Skip to main content Accessibility help

Statins and myocardial remodelling: cell and molecular pathways

  • Karen E. Porter (a1) and Neil A. Turner (a1)


The advent of statins has revolutionised the treatment of patients with raised plasma cholesterol and increased cardiovascular risk. However, the beneficial effects of this class of drugs are far greater than would be expected from lowering of cholesterol alone, and they appear to offer cardiovascular protection at multiple levels, primarily as a result of their pleiotropic activity. Indeed, their favourable effects on the heart seem to be mediated in part through reduced prenylation and subsequent inhibition of small GTPases, particularly those of the Rho family. Such statin-mediated effects are manifested by reduced onset of heart failure and improvements in cardiac dysfunction and remodelling in heart failure patients. Experimental studies have shown that statins mediate their effects on the two major resident cell types of the heart–cardiomyocytes and cardiac fibroblasts–and thus facilitate improvement of adverse remodelling of ischaemic or non-ischaemic aetiology. This review examines evidence for the cellular effects of statins in the heart, and discusses the underlying molecular mechanisms at the level of the cardiomyocyte (hypertrophy, cell death and contractile function) and the cardiac fibroblast (differentiation, proliferation, migration and extracellular matrix synthesis). The prospects for future therapies and ongoing clinical trials are also summarised.


Corresponding author

*Corresponding author: Karen E. Porter, Division of Cardiovascular and Neuronal Remodelling, Worsley Building, Clarendon Way, University of Leeds, Leeds LS2 9JT, UK. Email:


Hide All
1Steinberg, D. and Gotto, A.M. Jr. (1999) Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. Journal of the American Medical Association 282, 2043-2050
2Kannel, W.B. and McGee, D.L. (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59, 8-13
3Grundy, S.M. et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Journal of the American College of Cardiology 44, 720-732
4Istvan, E.S. and Deisenhofer, J. (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292, 1160-1164
5Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389
6Brugts, J.J. et al. (2009) The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. British Medical Journal 338, b2376
7Sacks, F.M. et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine 335, 1001-1009
8The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine 339, 1349-1357
9Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7-22
10Shepherd, J. et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 333, 1301-1307
11Baigent, C. et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278
12Ridker, P.M. et al. (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine 359, 2195-2207
13Cannon, C.P. et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 350, 1495-1504
14LaRosa, J.C. et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine 352, 1425-1435
15Pedersen, T.R. et al. (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Journal of the American Medical Association 294, 2437-2445
16Armitage, J. et al. (2010) Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376, 1658-1669
17de Lemos, J.A. et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Journal of the American Medical Association 292, 1307-1316
18Baigent, C. et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670-1681
19Davignon, J. (2004) Beneficial cardiovascular pleiotropic effects of statins. Circulation 109, III39-III43
20Kjekshus, J. et al. (1997) The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. Journal of Cardiac Failure 3, 249-254
21Node, K. et al. (2003) Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108, 839-843
22Corsini, A. et al. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacology and Therapeutics 84, 413-428
23Liao, J.K. and Laufs, U. (2005) Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 45, 89-118
24Pekkanen, J. et al. (1990) Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. New England Journal of Medicine 322, 1700-1707
25Liu, P.Y. et al. (2009) Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation 119, 131-138
26Ostad, M.A. et al. (2009) Flow-mediated dilation in patients with coronary artery disease is enhanced by high dose atorvastatin compared to combined low dose atorvastatin and ezetimibe: results of the CEZAR study. Atherosclerosis 205, 227-232
27Su, S.F. et al. (2000) Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension. American Journal of Cardiology 86, 514-518
28Young-Xu, Y. et al. (2003) Statins reduce the incidence of atrial fibrillation in patients with coronary artery disease. Journal of the American College of Cardiology 41 (Suppl. A), 301A
29Tsouli, S.G. et al. (2008) Should a statin be prescribed to every patient with heart failure? Heart Failure Reviews 13, 211-225
30Foody, J.M. et al. (2006) Statins and mortality among elderly patients hospitalized with heart failure. Circulation 113, 1086-1092
31Horwich, T.B., MacLellan, W.R. and Fonarow, G.C. (2004) Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. Journal of the American College of Cardiology 43, 642-648
32Ramasubbu, K. et al. (2008) Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. Journal of the American College of Cardiology 51, 415-426
33Tavazzi, L. et al. (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372, 1231-1239
34Khush, K.K. et al. (2007) Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the treating to new targets (TNT) study. Circulation 115, 576-583
35Scirica, B.M. et al. (2006) Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. Journal of the American College of Cardiology 47, 2326-2331
36Kumar, A. and Cannon, C.P. (2008) The role of statins in the prevention of heart failure after acute coronary syndrome. Heart Failure Clinics 4, 129-139
37Laufs, U., Custodis, F. and Bohm, M. (2008) Who does not need a statin: too late in end-stage renal disease or heart failure? Heart 94, 1138-1140
38Adam, O. et al. (2008) Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Circulation 118, 1285-1293
39Bauersachs, J. et al. (2001) Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104, 982-985
40Hasegawa, H. et al. (2003) 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats. Journal of Molecular and Cellular Cardiology 35, 953-960
41Hayashidani, S. et al. (2002) Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105, 868-873
42Luo, J.D. et al. (1999) Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clinical and Experimental Pharmacology and Physiology 26, 903-908
43Patel, R. et al. (2001) Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 104, 317-324
44Liao, J.K. (2002) Isoprenoids as mediators of the biological effects of statins. Journal of Clinical Investigation 110, 285-288
45Van Aelst, L. and Souza-Schorey, C. (1997) Rho GTPases and signaling networks. Genes and Development 11, 2295-2322
46Lezoualc'h, F. et al. (2008) Small GTP-binding proteins and their regulators in cardiac hypertrophy. Journal of Molecular and Cellular Cardiology 44, 623-632
47Adam, O. et al. (2007) Role of Rac1 GTPase activation in atrial fibrillation. Journal of the American College of Cardiology 50, 359-367
48Custodis, F. et al. (2006) Association of RhoGDIα with Rac1 GTPase mediates free radical production during myocardial hypertrophy. Cardiovascular Research 71, 342-351
49Maack, C. et al. (2003) Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108, 1567-1574
50Clerk, A. and Sugden, P.H. (2000) Small guanine nucleotide-binding proteins and myocardial hypertrophy. Circulation Research 86, 1019-1023
51Hunter, J.J. and Chien, K.R. (1999) Signaling pathways for cardiac hypertrophy and failure. New England Journal of Medicine 341, 1276-1283
52Brown, J.H., Del Re, D.P. and Sussman, M.A. (2006) The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circulation Research 98, 730-742
53Clerk, A. et al. (2001) Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1. Molecular and Cellular Biology 21, 1173-1184
54Satoh, M. et al. (2006) Requirement of Rac1 in the development of cardiac hypertrophy. Proceedings of the National Academy of Sciences of the United States of America 103, 7432-7437
55Lu, H. et al. (2006) Integrin-linked kinase expression is elevated in human cardiac hypertrophy and induces hypertrophy in transgenic mice. Circulation 114, 2271-2279
56Sah, V.P. et al. (1999) Cardiac-specific overexpression of RhoA results in sinus and atrioventricular nodal dysfunction and contractile failure. Journal of Clinical Investigation 103, 1627-1634
57Higashi, M. et al. (2003) Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circulation Research 93, 767-775
58Satoh, S. et al. (2003) Chronic inhibition of Rho kinase blunts the process of left ventricular hypertrophy leading to cardiac contractile dysfunction in hypertension-induced heart failure. Journal of Molecular and Cellular Cardiology 35, 59-70
59Wang, Y.X. et al. (2005) Inhibition of Rho-kinase by fasudil attenuated angiotensin II-induced cardiac hypertrophy in apolipoprotein E deficient mice. European Journal of Pharmacology 512, 215-222
60Hattori, T. et al. (2004) Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation 109, 2234-2239
61Bao, W. et al. (2004) Inhibition of Rho-kinase protects the heart against ischemia/reperfusion injury. Cardiovascular Research 61, 548-558
62Rikitake, Y. et al. (2005) Decreased perivascular fibrosis but not cardiac hypertrophy in ROCK1 + /- haploinsufficient mice. Circulation 112, 2959-2965
63Zhang, Y.M. et al. (2006) Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. FASEB Journal 20, 916-925
64Hunter, J.J. et al. (1995) Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. Journal of Biological Chemistry 270, 23173-23178
65Zheng, M. et al. (2004) Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. American Journal of Physiology. Heart and Circulatory Physiology 286, H424-H433
66Kai, H. et al. (1998) Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circulation Research 83, 594-601
67Jugdutt, B.I. (2003) Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 108, 1395-1403
68Porter, K.E. and Turner, N.A. (2009) Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacology and Therapeutics 123, 255-278
69Zhou, Q. and Liao, J.K. (2010) Pleiotropic effects of statins. Basic research and clinical perspectives. Circulation Journal 74, 818-826
70Brown, R.D. et al. (2005) The cardiac fibroblast: therapeutic target in myocardial remodeling and failure. Annual Review of Pharmacology and Toxicology 45, 657-687
71Camelliti, P., Borg, T.K. and Kohl, P. (2005) Structural and functional characterisation of cardiac fibroblasts. Cardiovascular Research 65, 40-51
72Weber, K.T. (2004) Fibrosis in hypertensive heart disease: focus on cardiac fibroblasts. Journal of Hypertension 22, 47-50
73Banerjee, I. et al. (2006) Dynamic interactions between myocytes, fibroblasts, and extracellular matrix. Annals of the New York Academy of Sciences 1080, 76-84
74Kohl, P. (2004) Cardiac cellular heterogeneity and remodelling. Cardiovascular Research 64, 195-197
75Camelliti, P., Green, C.R. and Kohl, P. (2006) Structural and functional coupling of cardiac myocytes and fibroblasts. Advances in Cardiology 42, 132-149
76Mann, D.L. and Bristow, M.R. (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111, 2837-2849
77Mital, S. and Liao, J.K. (2004) Statins and the myocardium. Seminars in Vascular Medicine 4, 377-384
78Oi, S. et al. (1999) Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. European Journal of Pharmacology 376, 139-148
79Nishikimi, T. et al. (2002) Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. European Journal of Pharmacology 453, 175-181
80Laufs, U. et al. (2002) Impact of HMG CoA reductase inhibition on small GTPases in the heart. Cardiovascular Research 53, 911-920
81Morikawa-Futamatsu, K. et al. (2006) HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1. Life Sciences 79, 1380-1390
82Hordijk, P.L. (2006) Regulation of NADPH oxidases: the role of Rac proteins. Circulation Research 98, 453-462
83Takemoto, M. et al. (2001) Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation 108, 1429-1437
84Choi, E.Y. et al. (2010) Rosuvastatin inhibits norepinephrine-induced cardiac hypertrophy via suppression of Gh. European Journal of Pharmacology 627, 56-62
85Hwang, K.C. et al. (1996) Alpha 1-adrenergic receptor coupling with Gh in the failing human heart. Circulation 94, 718-726
86Wu, L. et al. (2006) Simvastatin attenuates hypertrophic responses induced by cardiotrophin-1 via JAK-STAT pathway in cultured cardiomyocytes. Molecular and Cellular Biochemistry 284, 65-71
87Liu, J., Shen, Q. and Wu, Y. (2008) Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway. Life Sciences 82, 991-996
88Planavila, A. et al. (2008) Atorvastatin inhibits GSK-3beta phosphorylation by cardiac hypertrophic stimuli. Biochimica et Biophysica Acta 1781, 26-35
89Hauck, L. et al. (2007) Critical role for FoxO3a-dependent regulation of p21CIP1/WAF1 in response to statin signaling in cardiac myocytes. Circulation Research 100, 50-60
90Whelan, R.S., Kaplinskiy, V. and Kitsis, R.N. (2010) Cell death in the pathogenesis of heart disease: mechanisms and significance. Annual Review of Physiology 72, 19-44
91Webster, K.A. (2007) Programmed death as a therapeutic target to reduce myocardial infarction. Trends in Pharmacological Sciences 28, 492-499
92Verma, S. et al. (2004) Novel cardioprotective effects of pravastatin in human ventricular cardiomyocytes subjected to hypoxia and reoxygenation: beneficial effects of statins independent of endothelial cells. Journal of Surgical Research 119, 66-71
93Bergmann, M.W. et al. (2004) Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3β and transcription factor β-catenin. Journal of Molecular and Cellular Cardiology 37, 681-690
94Vilahur, G. et al. (2009) Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction. Atherosclerosis 206, 95-101
95Jones, S.P. et al. (2003) Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circulation Research 93, 697-699
96Ito, M. et al. (2004) Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism. Circulation 110, 412-418
97Demyanets, S. et al. (2006) Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro. Biochemical Pharmacology 71, 1324-1330
98Ogata, Y. et al. (2002) Fluvastatin induces apoptosis in rat neonatal cardiac myocytes: a possible mechanism of statin-attenuated cardiac hypertrophy. Journal of Cardiovascular Pharmacology 40, 907-915
99Rivera, D.M. and Lowes, B.D. (2005) Molecular remodeling in the failing human heart. Current Heart Failure Reports 2, 5-9
100Zheng, X. and Hu, S.J. (2005) Effects of simvastatin on cardiac performance and expression of sarcoplasmic reticular calcium regulatory proteins in rat heart. Acta Pharmacologica Sinica 26, 696-704
101Vaquero, M. et al. (2007) Effects of atorvastatin and simvastatin on atrial plateau currents. Journal of Molecular and Cellular Cardiology 42, 931-945
102Lee, Y.L., Blaha, M.J. and Jones, S.R. (2011) Statin therapy in the prevention and treatment of atrial fibrillation. Journal of Clinical Lipidology 5, 18-29
103Muhlhauser, U. et al. (2006) Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits. FASEB Journal 20, 785-787
104Schmechel, A. et al. (2009) Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. Cardiovascular Research 82, 100-106
105Souders, C.A., Bowers, S.L. and Baudino, T.A. (2009) Cardiac fibroblast: the renaissance cell. Circulation Research 105, 1164-1176
106Baudino, T.A. et al. (2008) Cell patterning: interaction of cardiac myocytes and fibroblasts in three-dimensional culture. Microscopy and Microanalysis 14, 117-125
107Krenning, G., Zeisberg, E.M. and Kalluri, R. (2010) The origin of fibroblasts and mechanism of cardiac fibrosis. Journal of Cellular Physiology 225, 631-637
108Zeisberg, E.M. and Kalluri, R. (2010) Origins of cardiac fibroblasts. Circulation Research 107, 1304-1312
109Sun, Y. and Weber, K.T. (2000) Infarct scar: a dynamic tissue. Cardiovascular Research 46, 250-256
110Willems, I.E. et al. (1994) The alpha-smooth muscle actin-positive cells in healing human myocardial scars. American Journal of Pathology 145, 868-875
111Shiroshita-Takeshita, A. et al. (2007) Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovascular Research 74, 75-84
112Moiseeva, O.M. et al. (2007) Effect of pravastatin on phenotypical transformation of fibroblasts and hypertrophy of cardiomyocytes in culture. Bulletin of Experimental Biology and Medicine 143, 54-57
113Haudek, S.B. et al. (2009) Rho kinase-1 mediates cardiac fibrosis by regulating fibroblast precursor cell differentiation. Cardiovascular Research 83, 511-518
114Xu, S.W. et al. (2009) Rac inhibition reverses the phenotype of fibrotic fibroblasts. PLoS One 4, e7438
115Akhmetshina, A. et al. (2008) Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. Arthritis and Rheumatism 58, 2553-2564
116Meyer-Ter-Vehn, T. et al. (2008) Lovastatin inhibits TGF-β-induced myofibroblast transdifferentiation in human tenon fibroblasts. Investigative Ophthalmology and Visual Science 49, 3955-3960
117Rodrigues-Diez, R. et al. (2008) Pharmacological modulation of epithelial mesenchymal transition caused by angiotensin II. Role of ROCK and MAPK pathways. Pharmaceutical Research 25, 2447-2461
118He, Y.P. et al. (2008) Involvement of ERK and AKT signaling in the growth effect of arginine vasopressin on adult rat cardiac fibroblast and the modulation by simvastatin. Molecular and Cellular Biochemistry 317, 33-41
119Martin, J. et al. (2005) In vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling. Clinical and Experimental Pharmacology and Physiology 32, 697-701
120Tian, B. et al. (2003) Angiotensin II modulates nitric oxide-induced cardiac fibroblast apoptosis by activation of AKT/PKB. American Journal of Physiology. Heart and Circulatory Physiology 285, H1105-H1112
121Xu, L. et al. (2006) Effects of simvastatin on DNA synthesis in rat cardiac fibroblasts. Nan Fang Yi Ke Da Xue Xue Bao 26, 205-207, 213
122Tian, J.W. et al. (2003) Effects of atorvastatin on the proliferation and collagen synthesis of rat cardiac fibroblasts. Zhonghua Yi Xue Za Zhi 83, 118-122
123Chen, J. and Mehta, J.L. (2006) Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. American Journal of Physiology. Heart and Circulatory Physiology 291, H1738-H1745
124Porter, K.E. et al. (2004) Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Cardiovascular Research 61, 745-755
125Porter, K.E. et al. (2004) Tumor necrosis factor α induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovascular Research 64, 507-515
126Turner, N.A. et al. (2007) Simvastatin inhibits TNFα-induced invasion of human cardiac myofibroblasts via both MMP-9-dependent and -independent mechanisms. Journal of Molecular and Cellular Cardiology 43, 168-176
127Jugdutt, B.I. (2003) Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough? Circulation 108, 1395-1403
128Adam, O. et al. (2010) Rac1-induced connective tissue growth factor regulates connexin 43 and N-cadherin expression in atrial fibrillation. Journal of the American College of Cardiology 55, 469-480
129Shyu, K.G. et al. (2010) Mechanism of the inhibitory effect of atorvastatin on endoglin expression induced by transforming growth factor-β1 in cultured cardiac fibroblasts. European Journal of Heart Failure 12, 219-226
130Porter, K.E. and Turner, N.A. (2002) Statins for the prevention of vein graft stenosis: a role for inhibition of matrix metalloproteinase-9. Biochem Soc Trans 30, 120-126
131Luan, Z., Chase, A.J. and Newby, A.C. (2003) Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23, 769-775
132Tousoulis, D. et al. (2005) Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. European Journal of Heart Failure 7, 1126-1132
133Sola, S. et al. (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. Journal of the American College of Cardiology 47, 332-337
134Zhang, J. et al. (2005) Simvastatin regulates myocardial cytokine expression and improves ventricular remodeling in rats after acute myocardial infarction. Cardiovascular Drugs and Therapy 19, 13-21
135Wallace, C.K. et al. (2005) Simvastatin decreases myocardial tumor necrosis factor α content in heart transplant recipients. Journal of Heart and Lung Transplantation 24, 46-51
136Turner, N.A. et al. (2007) Mechanism of TNFα-induced IL-1α, IL-1β and IL-6 expression in human cardiac fibroblasts: effects of statins and thiazolidinediones. Cardiovascular Research 76, 81-90
137Eccles, K.A. et al. (2008) Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow. Atherosclerosis 200, 69-79
138Arnaud, C., Braunersreuther, V. and Mach, F. (2005) Toward immunomodulatory and anti-inflammatory properties of statins. Trends in Cardiovascular Medicine 15, 202-206
139Beltowski, J., Wojcicka, G. and Jamroz-Wisniewska, A. (2009) Adverse effects of statins – mechanisms and consequences. Current Drug Safety 4, 209-228
140Marcoff, L. and Thompson, P.D. (2007) The role of coenzyme Q10 in statin-associated myopathy: a systematic review. Journal of the American College of Cardiology 49, 2231-2237
141Moosmann, B. and Behl, C. (2004) Selenoprotein synthesis and side-effects of statins. Lancet 363, 892-894
142Olson, M.F. (2008) Applications for ROCK kinase inhibition. Current Opinion in Cell Biology 20, 242-248
143Dong, M. et al. (2010) Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discovery Today 15, 622-629
144Bain, J. et al. (2007) The selectivity of protein kinase inhibitors: a further update. Biochemical Journal 408, 297-315

The NIH-supported website provides a searchable database of recent, ongoing and upcoming clinical trials conducted in the USA and around the world:

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Expert Reviews in Molecular Medicine
  • ISSN: -
  • EISSN: 1462-3994
  • URL: /core/journals/expert-reviews-in-molecular-medicine
Please enter your name
Please enter a valid email address
Who would you like to send this to? *


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed